Latest Quarterly Report
Filed: 2026-05-08
Key Insights
- Company executed a reverse stock split on February 2, 2026, indicating potential financial distress or efforts to maintain Nasdaq listing compliance requirements.
- The filing shows multiple series of convertible preferred stock (Series A, B, and C) and warrants outstanding, suggesting significant dilution to common shareholders from prior financing rounds.
- As a smaller reporting company and non-accelerated filer in the biotech sector, Atossa has reduced regulatory disclosure requirements, limiting transparency into R&D progress and clinical developments for investors.
- The company maintains money market funds as fair value Level 1 and Level 2 assets, suggesting it still has some cash reserves, though the extent and runway are unclear from the truncated filing content.